PCRXPacira BioSciences, Inc.
$36.41+54% 1Y
$36.41
$19.1652 weeks$36.41
Latest close: a new 52-week highOct 8, 2026what changed →
PCRX in its own filings
Nothing in PCRX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
323
Events found in the filings · across 1,297 filings · the record starts in 2010
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 8, 2026
Most recent filing · Form 8-K
- Record starts
- Nov 29, 2010
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant2 occurrences
- 2016-02-26
- Material impairmenthistorical
- 2017-06-29
- SEC comment-letter activity16 occurrences
- 2023-10-24
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Parent”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent …Material agreement entered · Form 8-K
- Aug 4, 2026Pacira BioSciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 30, 2026On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the “Subsidiary”), entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Zimmer, Inc. (the “Purchaser”), a subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”)Material agreement entered · Form 8-K
- Jun 11, 2026Amended and Restated 2014 Employee Stock Purchase Plan On June 9, 2026, Pacira BioSciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) in Parsippany, New Jersey and via live webcast online at www.cesonlineservices.com/pcrx26_vm, at which the Company’s stockholders approved …Director or officer change · Form 8-K
- Apr 30, 2026Pacira BioSciences Reports First Quarter 2026 Financial Results.Earnings release · press release
- Feb 26, 2026Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results.Earnings release · press release
- Jan 28, 2026On January 27, 2026, the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”), pursuant to the Amended and Restated Certificate of Incorporation of the Company and the Third Amended and Restated Bylaws of the Company, approved an increase of the size of the Board from nine directors to 10 …Director or officer change · Form 8-K
- Nov 6, 2025Pacira BioSciences Reports Third Quarter 2025 Financial Results;.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore